BioSpace News Archive

Business

Elucid Appoints Dr. Michael Lesh to Board of Directors

Elucid, Inc today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors.

November 3, 2022
·
2 min read
Business

Clinical Evaluation of Aptinyx’s NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant

Aptinyx Inc. today announced the finalization of a $5.6 million grant under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative, supporting the development of NYX-783 for the treatment of opioid use disorder (OUD).

November 3, 2022
·
7 min read
Business

Organon Reports Results for the Third Quarter Ended September 30, 2022

Organon (NYSE: OGN) (the “company”), today announced its results for the third quarter ended September 30, 2022.

November 3, 2022
·
24 min read
Genetown

Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek®

Rhythm Pharmaceuticals, Inc. announced a total of 11 presentations at The Obesity Society’s Annual Meeting at ObesityWeek® being held November 1-4, 2022 in San Diego.

November 3, 2022
·
15 min read
Business

MediWound to Report Third Quarter 2022 Financial Results

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced that the Company will release its financial results for the third quarter ended September 30, 2022 on Tuesday, November 15, 2022.

November 3, 2022
·
2 min read
Business

Replimune Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

Replimune Group, Inc. announced financial results for the fiscal second quarter ended September 30, 2022 and provided a business update.

November 3, 2022
·
13 min read
Drug Development

Aramis Biosciences Completes Enrollment of its Phase II Clinical Trial Evaluating A197 for the Treatment of Dry Eye Disease

Aramis Biosciences, Inc. announced the completion of enrollment in its Phase II proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease.

November 3, 2022
·
2 min read
Drug Development

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva Biologics announced the first patient has been dosed in Cohort 2 of its Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 in allogeneic hematopoietic cell transplant recipients for the prevention of acute graft-versus-host-disease.

November 3, 2022
·
7 min read
Business

aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results

aTyr Pharma, Inc. announced that it will report third quarter 2022 financial results and provide a corporate update after the market close on Thursday, November 10, 2022.

November 3, 2022
·
1 min read
Business

MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results

MiNK Therapeutics, Inc. reported financial results for the third quarter 2022 and provided a corporate update.

November 3, 2022
·
6 min read